LITHIUM CITRATE Drug Patent Profile

« Back to Dashboard

Which patents cover Lithium Citrate, and when can generic versions of Lithium Citrate launch?

Lithium Citrate is a drug marketed by Hikma, Pai Holdings Pharm, Rubicon Research, and Sciegen Pharms. and is included in four NDAs.

The generic ingredient in LITHIUM CITRATE is lithium citrate. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the lithium citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lithium Citrate

A generic version of LITHIUM CITRATE was approved as lithium citrate by PAI HOLDINGS PHARM on May 21^st, 1986.

Summary for LITHIUM CITRATE

US Patents:	0
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	3,183
Drug Prices:	Drug price information for LITHIUM CITRATE
DailyMed Link:	LITHIUM CITRATE at DailyMed

See drug prices for LITHIUM CITRATE

Recent Clinical Trials for LITHIUM CITRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mental Health Services in the Capital Region, Denmark	Phase 4
Haining Health-Coming Biotech Co., Ltd.	Phase 2
Alphacait, LLC	Phase 2

See all LITHIUM CITRATE clinical trials

Pharmacology for LITHIUM CITRATE

Drug Class

Mood Stabilizer

Anatomical Therapeutic Chemical (ATC) Classes for LITHIUM CITRATE

N05AN	Lithium
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for LITHIUM CITRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	LITHIUM CITRATE	lithium citrate	SYRUP;ORAL	018421-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sciegen Pharms	LITHIUM CITRATE	lithium citrate	SYRUP;ORAL	217183-001	Mar 18, 2024	AA	RX	No	No
Pai Holdings Pharm	LITHIUM CITRATE	lithium citrate	SYRUP;ORAL	070755-001	May 21, 1986	AA	RX	No	No
Rubicon Research	LITHIUM CITRATE	lithium citrate	SYRUP;ORAL	218036-001	Aug 14, 2023	AA	RX	No	Yes

Lithium Citrate Market Dynamics, Patent Status, and Financial Trajectory

Last updated: October 15, 2026

Lithium citrate is an established generic lithium salt used primarily as an oral solution for bipolar disorder and related mood disorders. Its commercial profile is defined by low molecular complexity, limited patent protection, narrow therapeutic management, and small-volume manufacturing. Revenue is fragmented and no major pharmaceutical company publicly reports lithium citrate sales as a standalone product.

The market’s main economic variables are prescription demand, availability of oral liquid products, pharmacy reimbursement, active pharmaceutical ingredient supply, and substitution with lithium carbonate tablets or extended-release products. New chemical entity exclusivity, biosimilar competition, and meaningful branded patent barriers are not material factors.

What is lithium citrate and how is it used?

Lithium citrate is an oral lithium formulation administered as a solution. The pharmacologically active component is the lithium ion, not the citrate counterion.

A commonly used concentration is 8 mEq of lithium per 5 mL, approximately equivalent to 300 mg of lithium carbonate in lithium-ion content. Dosing must be individualized through serum lithium monitoring because the therapeutic range is narrow and toxicity can occur with relatively small changes in exposure (DailyMed, n.d.).

What conditions does lithium citrate treat?

Lithium products are used for:

• Acute manic episodes and maintenance treatment in bipolar disorder.
• Reduction of relapse risk in bipolar disorder.
• Selected off-label psychiatric uses under specialist supervision.

The FDA-approved indication depends on the specific product label. Lithium citrate solution and lithium carbonate products are not automatically interchangeable on a milligram basis because their salt weights and concentrations differ.

Why does the oral solution matter commercially?

The liquid formulation has a narrower customer base than lithium carbonate tablets but retains value for:

• Patients unable to swallow tablets.
• Pediatric or adolescent patients when prescribed.
• Patients requiring flexible dose titration.
• Long-term-care settings using liquid medication administration.
• Patients receiving enteral medication.

This creates a specialized generic market rather than a mass-market pharmaceutical category.

What is the FDA regulatory status of lithium citrate?

Lithium citrate oral solution is a prescription drug subject to FDA approval, labeling, manufacturing, pharmacovigilance, and current good manufacturing practice requirements. Products may be approved through abbreviated new drug applications when the applicant demonstrates pharmaceutical equivalence and bioequivalence or otherwise satisfies the applicable approval standard (FDA, n.d.-a).

The FDA’s regulatory framework does not treat lithium citrate as a biosimilar. It is a chemically synthesized small-molecule drug. Generic applicants therefore use the ANDA pathway rather than the abbreviated biologics pathway.

Does lithium citrate have FDA exclusivity?

Lithium citrate has no commercially relevant remaining new chemical entity exclusivity. The active lithium therapy dates to the nineteenth century, and the marketed product category has long been generic.

Any exclusivity attached to a newly approved formulation would depend on the specific application and regulatory designation. A conventional generic lithium citrate solution would not normally receive five-year NCE exclusivity. Pediatric exclusivity, orphan exclusivity, or other special periods would require a product-specific FDA designation.

What is the Orange Book status of lithium citrate?

The Orange Book lists FDA-approved prescription drug products and identifies relevant patents and regulatory exclusivity. For an old generic category such as lithium citrate, the principal commercial question is whether a specific marketed product has an active listed formulation or method-of-use patent.

The active ingredient itself is not protected by a modern composition-of-matter patent. Any current Orange Book protection would more likely relate to:

• A particular liquid formulation.
• A dosing regimen.
• A delivery system.
• A combination product.
• A manufacturing process, if eligible for listing and relevant to the approved product.

Orange Book status must be assessed by product, applicant, dosage form, and application number. It cannot be inferred solely from the active ingredient name (FDA, n.d.-b).

How many patents cover lithium citrate?

No commercially important patent estate is generally associated with lithium citrate as an active ingredient. The practical patent count for the molecule is therefore materially lower than for newer branded psychiatric drugs.

Potentially relevant patents can still arise around:

Protection category	Commercial relevance
Lithium citrate composition	Minimal for the legacy active ingredient
Oral solution formulation	Possible, but generally narrow
Taste masking and excipients	Possible, with limited blocking power
Dosing method	May affect labeling or litigation scope
Manufacturing process	Can create supply or process advantages
Packaging and dispensing	Usually weak as a market barrier
Combination therapy	Relevant only to a specific combination product

A process patent may raise manufacturing costs without preventing all generic entry. A formulation patent can be more relevant if it covers the only commercially practical concentration, stability profile, or dispensing system.

When does lithium citrate lose exclusivity?

Lithium citrate effectively lost core exclusivity decades ago. The product is already in the post-exclusivity generic phase.

There is no single future “loss of exclusivity” date comparable to a branded drug approaching patent expiration. Market entry is controlled by:

1. FDA approval of individual generic applications.
2. Commercial willingness to manufacture a low-volume liquid.
3. API availability and quality compliance.
4. Pharmacy and wholesaler economics.
5. Supply continuity.

This distinction matters financially. The key risk is not a sudden patent cliff. It is a supply shock, product discontinuation, or price compression after a new supplier enters.

Are there Paragraph IV challenges for lithium citrate?

Paragraph IV litigation is unlikely to be a central issue for conventional lithium citrate products because the molecule is long generic and does not depend on an active branded patent estate.

A Paragraph IV certification is relevant when an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. For lithium citrate, litigation would be more plausible if a sponsor listed a newer formulation or delivery patent.

The expected legal pattern is therefore:

• Limited litigation over the basic lithium citrate molecule.
• Possible disputes over liquid formulation claims.
• Possible patent disputes involving a branded reformulation.
• Greater exposure to FDA manufacturing or product-quality actions than to patent injunctions.

What formulations are protected by lithium citrate patents?

The most commercially defensible formulation concepts would involve oral liquids with:

• Improved chemical stability.
• Controlled lithium concentration.
• Reduced precipitation.
• Improved taste.
• Longer shelf life after opening.
• Child-resistant packaging.
• Unit-dose packaging.
• Compatibility with enteral administration.

These features can support product differentiation, but they do not necessarily create durable market exclusivity. Generic competitors may design around excipient combinations, concentration ranges, container systems, or manufacturing parameters.

The clinical value of formulation patents is also constrained by the requirement to maintain accurate lithium dosing. A formulation that improves taste but complicates dose measurement may have limited commercial adoption.

How does lithium citrate compare with lithium carbonate?

Lithium carbonate is the dominant comparator and usually the larger commercial product category.

Metric	Lithium citrate	Lithium carbonate
Common dosage form	Oral solution	Immediate- and extended-release tablets or capsules
Primary commercial use	Patients needing liquid administration	Broad adult maintenance and acute treatment
Dose flexibility	High	Lower with fixed-strength tablets
Manufacturing complexity	Liquid stability and packaging	Solid-dose compression and release control
Patient base	Specialized	Broad
Patent risk	Low for legacy products	Low for legacy products, with possible formulation patents
Substitution risk	High from carbonate liquid or tablets	High from other carbonate products
Supply sensitivity	Potentially high because of fewer suppliers	Usually broader supplier base

Lithium citrate can command a higher price per active treatment course than commodity lithium carbonate when it is supplied by only one or two manufacturers. That premium reflects formulation and supply economics, not strong intellectual property.

What is the competitive landscape for lithium citrate?

Competition is likely fragmented among specialty generic manufacturers, contract manufacturers, and pharmaceutical companies that maintain small portfolios of liquids and difficult-to-source medicines.

The market has several structural characteristics:

• Low entry barriers at the molecule level.
• Higher practical barriers for validated liquid manufacturing.
• Limited incentive to add capacity because total demand is relatively small.
• High sensitivity to one manufacturer’s discontinuation.
• Contracting pressure from wholesalers, hospitals, and pharmacy benefit managers.
• Potential for temporary price increases during shortages.

A company with an established oral-liquid facility, validated stability data, and reliable lithium API supply has a stronger position than a company relying solely on a low-cost ANDA strategy.

Which companies are challenging the market?

Public data do not establish a stable, comprehensive competitor list for lithium citrate because generic suppliers can change by country, product listing, and supply arrangement. The relevant competitive set should be identified through FDA product databases, National Drug Code listings, wholesaler availability, and current label records rather than historical brand references.

Legacy brands such as Eskalith and Lithonate are not reliable indicators of current market competition. Their historical presence does not establish current commercial supply.

What is the financial trajectory for lithium citrate?

Lithium citrate has a mature, low-growth financial profile. Public companies generally do not disclose revenue, gross margin, or prescription volume for the product separately. Standalone market-size estimates should therefore be treated cautiously unless they identify the exact geography, dosage form, channel, and supplier set.

The expected financial trajectory is:

Mature demand

Underlying demand is linked to diagnosed bipolar disorder, long-term maintenance treatment, and continued clinical use of lithium. Lithium remains an important low-cost mood stabilizer, but treatment growth is constrained by monitoring requirements, adverse effects, renal and thyroid risks, and competition from newer psychiatric therapies.

Stable but narrow volume

Volume is likely to remain concentrated in patients who need liquid administration. Broad growth in bipolar treatment does not translate directly into equivalent growth for lithium citrate because many patients receive lithium carbonate tablets or non-lithium medicines.

Price volatility

Pricing can remain low during multi-supplier competition and rise sharply when a supplier exits. Generic oral liquids are more exposed to temporary price dislocations than high-volume tablets because fixed manufacturing and compliance costs are spread across fewer units.

Margin pressure

Long-term margins face pressure from:

• Generic substitution.
• Pharmacy reimbursement controls.
• Wholesaler purchasing power.
• API and packaging costs.
• Batch-release requirements.
• Small production runs.
• Inventory expiration risk.

A supplier can generate attractive margins during a shortage, but those margins may normalize quickly after additional supply enters.

Limited value from patent monetization

Licensing income, patent royalties, and settlement proceeds are unlikely to be major revenue sources for conventional lithium citrate. Commercial value is more likely to come from dependable supply, regulatory execution, and distribution access.

What manufacturing and IP barriers affect lithium citrate?

The principal barriers are operational rather than patent-based.

Manufacturers must control:

• Lithium concentration and dose uniformity.
• Solution homogeneity.
• Chemical stability.
• Microbial quality.
• Container-closure integrity.
• Accurate measuring devices.
• Labeling and medication-error risks.
• Batch-to-batch consistency.

Lithium is associated with a narrow therapeutic index, which increases the cost of quality failures. A concentration error can create direct patient-safety exposure and regulatory risk. This makes manufacturing controls commercially important even when the underlying molecule is unprotected.

API supply also matters. Lithium salts are inexpensive relative to complex APIs, but suppliers still need qualified material, validated analytical methods, and compliant documentation. Shortages can result from finished-product manufacturing failures rather than a global shortage of lithium itself.

What generic launch scenarios exist for lithium citrate?

Three scenarios are commercially plausible.

Scenario	Market effect	Financial result
Stable multi-supplier supply	Low price volatility and predictable access	Low to moderate margins
Supplier exit or FDA disruption	Temporary shortage and higher prices	Short-term margin expansion for available inventory
New entrant with reliable liquid capacity	Greater access and price compression	Lower incumbent revenue and margin

A new entrant is most likely to succeed if it has an existing oral-liquid platform, an approved or readily approvable concentration, national distribution, and a supply contract with institutional buyers.

Is lithium citrate a strong pharmaceutical investment opportunity?

Lithium citrate is generally a defensive niche generic rather than a high-growth pharmaceutical asset. Its strengths are established clinical demand, low active-ingredient complexity, and limited direct patent competition.

Its weaknesses are small addressable volume, weak brand differentiation, limited pricing power outside shortage periods, and exposure to generic procurement pressure. The strongest commercial thesis is operational reliability in an undersupplied niche, not patent exclusivity or rapid market expansion.

Key Takeaways

• Lithium citrate is a mature generic lithium formulation, usually supplied as an oral solution.
• The active lithium ion is clinically important, but the molecule has no meaningful modern composition-of-matter exclusivity.
• FDA exclusivity, biosimilar competition, and major Paragraph IV litigation are not central market drivers.
• Formulation, packaging, stability, and manufacturing patents may exist but are likely narrower than the active-ingredient protection associated with newer drugs.
• Lithium carbonate is the main substitute and has a broader commercial market.
• Financial performance is driven by supply concentration, reimbursement, API availability, and liquid-manufacturing capacity.
• Public companies generally do not report lithium citrate revenue separately.
• The principal investment opportunity is shortage-resilient supply, not long-term patent monetization.

FAQs

Is lithium citrate still commercially available?

Availability depends on country, manufacturer, dosage form, and current supply conditions. Oral-liquid products can have less consistent availability than lithium carbonate tablets because fewer manufacturers maintain liquid production capacity.

Is lithium citrate safer than lithium carbonate?

Neither salt is inherently free of lithium-related toxicity. Safety depends on lithium exposure, renal function, hydration, interacting medicines, serum monitoring, and accurate dosing. Salt-to-salt conversion must use lithium-equivalent content rather than milligram weight alone.

Can a generic manufacturer obtain a patent on lithium citrate?

A new composition-of-matter patent on the old active ingredient would generally face severe prior-art problems. A manufacturer may pursue patents covering a formulation, delivery system, packaging configuration, stability improvement, or manufacturing process.

Does lithium citrate have biosimilar competition?

No. Lithium citrate is a small-molecule drug, so competing products are generics or authorized generic-type products, not biosimilars.

What is the main commercial risk for lithium citrate suppliers?

The main risk is supply and quality disruption in a low-volume product category. A manufacturing failure, product discontinuation, or regulatory action can remove a large share of available supply, while a new entrant can later compress pricing.

References

1. DailyMed. (n.d.). Lithium citrate oral solution prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (n.d.-d). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages/